Cargando…

CD39: the potential target in small cell lung cancer

BACKGROUND: It has been proven that the treatment window of small cell lung cancer (SCLC) is short, so it is vital to find other possible therapeutic targets. CD39 inhibits natural killer (NK) cells and promotes the occurrence and metastasis of tumors. There has been little research about the role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shanhao, Wu, Shengyu, Zhang, Liping, Zhang, Wei, Liu, Yu, Chen, Bin, Zhao, Sha, Li, Wei, Sun, Chenglong, Wang, Lei, Jia, Keyi, Wang, Hao, Chen, Peixin, Wu, Chunyan, Zhu, Junjie, He, Yayi, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481638/ https://www.ncbi.nlm.nih.gov/pubmed/32953520 http://dx.doi.org/10.21037/tlcr-20-798

Ejemplares similares

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
por: Wang, Hao, et al.
Publicado: (2021)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2023)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
por: Wang, Hao, et al.
Publicado: (2019)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review
por: Li, Wei, et al.
Publicado: (2020)

Immunotherapy as a treatment for small cell lung cancer: a case report and brief review
por: Wu, Yan, et al.
Publicado: (2020)

mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2021)

Alterations of DNA damage repair in cancer: from mechanisms to applications
por: Jiang, Minlin, et al.
Publicado: (2020)

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19
por: Guo, Haoyue, et al.
Publicado: (2020)

Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure
por: Chen, Peixin, et al.
Publicado: (2020)

cGAS-STING, an important pathway in cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2020)

Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research
por: Wang, Hao, et al.
Publicado: (2021)

Percutaneous Microwave Coagulation Therapy: A Promising Therapeutic Method for Breaking the Barrier of the Intertumor Heterogeneity
por: Guo, Haoyue, et al.
Publicado: (2021)

Collection on reports of molecules linked to epithelial-mesenchymal transition in the process of treating metastasizing cancer: a narrative review
por: Cai, Yiyi, et al.
Publicado: (2021)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
por: Wu, Fengying, et al.
Publicado: (2021)

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
por: Chen, Shen, et al.
Publicado: (2019)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Non‐small cell lung cancer in China
por: Chen, Peixin, et al.
Publicado: (2022)

sLAG-3 in non-small-cell lung cancer patients’ serum
por: He, Yayi, et al.
Publicado: (2018)

Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer
por: Xu, Yi, et al.
Publicado: (2020)

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)
por: Guo, Haoyue, et al.
Publicado: (2021)

Early diagnosis of lung cancer: which is the optimal choice?
por: Ning, Jing, et al.
Publicado: (2021)

The diagnostic performance of endobronchial ultrasound with Xpert MTB/RIF Ultra in smear-negative pulmonary tuberculosis
por: Yao, Lan, et al.
Publicado: (2023)

Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor
por: Fang, Qiyu, et al.
Publicado: (2022)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

A narrative review of tumor heterogeneity and challenges to tumor drug therapy
por: Zhu, Liang, et al.
Publicado: (2021)

The Metal Coordination of sCD39 during ATP Hydrolysis
por: Chen, Wei, et al.
Publicado: (2001)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Risk-score model to predict prognosis of malignant airway obstruction after interventional bronchoscopy
por: Jiang, Minlin, et al.
Publicado: (2021)

High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma
por: Wu, Jie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mvoucrp4fdp93l7argeldbcuqq